Pay in 4 interest-free payments of $6.03 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Journal of molecular medicine (Berlin, Germany), 95(3), 323333
SOLD FOR RESEARCH ONLY.
If you are under 21 years old or do not agree with these terms, you must leave this website immediately
Rare but serious events encompass provocation or exacerbation of seizures in susceptible individuals and hypersensitivity reactions ranging from urticaria to anaphylaxis
.jpg)
While lixisenatide was found to be the only GLP-1RA subtype to increase the risk of MI, it is important to consider that the ELIXA trial, which studied lixisenatide in patients with T2DM, had the highest risk population as it included participants with recent acute coronary events in the past 180 days [40]
